EL7.AI
StocksMediumUpdated•Originally published 30 July 2026•Updated 31 July 2026•
1 min read

Castle Biosciences Raises 2026 Guidance Following Strong Q2 Results

Key Facts

1Castle Biosciences reported a Q2 loss of $0.07 per share, significantly beating the Zacks Consensus Estimate of a $0.44 loss.
2Fulgent Genetics reported a Q2 loss of $0.58 per share, missing the Zacks Consensus Estimate of a $0.46 loss.

In a move reflecting growing operational optimism, Castle Biosciences has raised its full-year 2026 revenue guidance following a strong quarterly performance. The company reported a Q2 loss of $0.07 per share, significantly beating analyst estimates of a $0.44 loss, while simultaneously increasing its annual revenue outlook to a range of $365 million to $375 million. Conversely, sector peer Fulgent Genetics reported a wider-than-expected loss of $0.58 per share against an anticipated $0.46 loss.

The updated guidance is supported by expectations for TissueCypher volume growth between 50% and 52%, signaling robust demand for its diagnostic products. According to market data, these divergent results highlight Castle Biosciences' superior cost management relative to Fulgent Genetics as the medical laboratory sector navigates varying revenue and operational pressures.

Regarding price action, CSTL stood at $23.89 while FLGT closed at $19.63 (close of July 28, 2026). With no direct economic catalysts in the upcoming calendar, traders will focus on the market's reaction to the guidance hike; CSTL recently traded between $23.76 and $24.77, while FLGT moved between $19.42 and $19.91.